ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation

Reuters

2025/06/24

ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation

ImmunoPrecise Antibodies Ltd. $(IPA)$, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared "Achilles' heel" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545676289"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545676289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545676289?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545676289","market":"nz","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. <a href=\"https://laohu8.com/S/IPA\">$(IPA)$</a>, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 19:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. <a href=\"https://laohu8.com/S/IPA\">$(IPA)$</a>, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL8tjm8z:1","article_id":"2545676289","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545676289","pubTimestamp":1750762941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation. ImmunoPrecise Antibodies Ltd. , a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.Disclaimer: This news brief was","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"ImmunoPrecise Antibodies宣布通用登革热疫苗开发取得突破，人工智能驱动的安全性和有效性验证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n    \n\n        ImmunoPrecise Antibodies Ltd. $(IPA)$, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}